3-溴-5-氟-2-甲基吡啶 | 1211542-29-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-溴-5-氟-2-甲基吡啶
• 中文别名: 2-甲基-3-溴-5-氟吡啶
• 英文名称: 3-bromo-5-fluoro-2-methylpyridine
• CAS: 1211542-29-8
• 化学式: C₆H₅BrFN
• 分子量: 190.015
• InChiKey: FDUMMEFEKHPQBG-UHFFFAOYSA-N

物化性质

• 沸点：
  166.1±35.0 °C(Predicted)
• 密度：
  1.592±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

制备方法与用途

简介

3-溴-5-氟-2-甲基吡啶是一种有机中间体，可通过一步反应由2,3-二溴-5-氟吡啶和甲基硼酸制备得到。有文献报道其可用于制备WDR5抑制剂。

制备

3-溴-5-氟-2-甲基吡啶的制备过程如下：将2,3-二溴-5-氟吡啶（5.0g，19.6 mmol）、四(三苯基膦)钯（Pd(PPb)4，1.13g，0.98mmol）和甲基硼酸（3.52g，58.9mmol）溶解在二噁烷（50mL）中。接着加入碳酸钾（K2CO3，8.13g，58.9mmol）与水（10mL）。用氮气清洗混合物后，在密封容器内加热至110℃并维持16小时。

冷却后的混合物在水中与乙酸乙酯（EtOAc）之间分配，并使有机层和水层分离。使用乙酸乙酯（2×50mL）萃取水相，用盐水（50mL）冲洗合并的有机层并进行干燥、过滤及浓缩处理。残余物通过硅胶柱层析纯化，洗脱剂为1-3％乙酸乙酯/己烷溶液，得到白色固体产物（产率32％）。质谱（APCI）分析显示其质量数为190.2 (M+)。

反应信息

• 作为反应物：
  描述：

  3-溴-5-氟-2-甲基吡啶 在 三乙烯二胺 、 selenium(IV) oxide 、 copper(l) iodide 、 2,2,6,6-四甲基-3,5-庚二酮 、 乙酸酐 、 三溴化硼 、 potassium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 58.0h， 生成
  参考文献：
  名称：

  Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group

  摘要：

  Members of the catechol diether class are highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase (NNRTIs). The most active compounds yield EC50 values below 0.5 nM in assays using human T-cells infected by wild-type HIV-1. However, these compounds such as rilpivirine, the most recently FDA-approved NNRTI, bear a cyanovinylphenyl (CVP) group. This is an uncommon substructure in drugs that gives reactivity concerns. In the present work, computer simulations were used to design bicyclic replacements for the CVP group. The predicted viability of a 2-cyanoindolizinyl alternative was confirmed experimentally and provided compounds with 0.4 nM activity against the wild-type virus. The compounds also performed well with EC50 values of 10 nM against the challenging HIV-1 variant that contains the Lys103Asn/Tyr181Cys double mutation in the RT enzyme. Indolyl and benzofuranyl analogues were also investigated; the most potent compounds in these cases have EC50 values toward wild-type HIV-1 near 10 nM and high-nanomolar activities toward the double-variant. The structural expectations from the modeling were much enhanced by obtaining an X-ray crystal structure at 2.88 Å resolution for the complex of the parent 2-cyanoindolizine 10b and HIV-1 RT. The aqueous solubilities of the most potent indolizine analogues were also measured to be ~40 μg/mL, which is similar to that for the approved drug efavirenz and ~1000-fold greater than for rilpivirine.

  DOI：

  10.1021/ja408917n
• 作为产物：
  描述：

  tert-butyl N-(tert-butoxycarbonyl)-N-(5-fluoro-2-methylpyridin-3-yl)carbamate 在 氢溴酸 、 sodium nitrite 、 copper(I) bromide 作用下， 以 水 为溶剂， 反应 1.5h， 以45%的产率得到3-溴-5-氟-2-甲基吡啶
  参考文献：
  名称：

  [EN] GCN2 MODULATING COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS MODULATEURS DE GCN2 ET LEURS UTILISATIONS

  摘要：

  本文提供了化合物、组合物和方法，有助于调节GCN2的活性，并用于治疗相关的疾病和疾病（例如癌症和神经退行性疾病）。

  公开号：

  WO2022159745A1

文献信息

• [EN] TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS<br/>[FR] DÉRIVÉS DE TROPOLONE ET LEURS TAUTOMÈRES POUR LA RÉGULATION DU FER CHEZ LES ANIMAUX
  申请人：AMBYS MEDICINES INC

  公开号：WO2021076945A1

  公开（公告）日：2021-04-22

  Disclosed are a series of compounds or their tautomers having a general structure represented by Formula la or lb and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula la or lb compounds or tautomers or pharmaceutically acceptable salts thereof.

  本文披露了一系列化合物或其互变异构体，其具有由化学式Ia或Ib表示的一般结构以及其药学上可接受的盐。还披露了包括所述化合物或互变异构体或其药学上可接受的盐的药物组合物。进一步的披露涉及一种治疗与铁调节失调或铁稳态功能异常相关的疾病或症状的方法，包括向需要的受试者施用化学式Ia或Ib化合物或互变异构体或其药学上可接受的盐的治疗有效量。
• [EN] (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS<br/>[FR] (AZA) INDAZOLYL-ARYLE SULFONAMIDE ET COMPOSÉS APPARENTÉS ET LEUR UTILISATION DANS LE TRAITEMENT D'ÉTATS MÉDICAUX
  申请人：HIBERCELL INC

  公开号：WO2020210828A1

  公开（公告）日：2020-10-15

  The invention provides (aza)indazolyl-aryl sulfonamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting GCN2 activity.

  这项发明提供了(aza)吲哚基芳基磺酰胺及相关化合物、药物组合物，以及它们在治疗医疗状况（如癌症）和抑制GCN2活性中的用途。
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DES TRK KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011006074A1

  公开（公告）日：2011-01-13

  Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

  式（I）的化合物及其盐，其中R1、R2、R3、R4、X、Y和n的含义如规范中所述，是Trk激酶的抑制剂，并且在治疗可以用Trk激酶抑制剂治疗的疾病中具有用处，如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
• [EN] CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS<br/>[FR] CARBOXAMIDES UTILISÉS EN TANT QUE MODULATEURS DE CANAUX SODIQUES
  申请人：VERTEX PHARMA

  公开号：WO2020146682A1

  公开（公告）日：2020-07-16

  Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

  提供了一种用作钠通道抑制剂的化合物，以及它们的药物可接受的盐。还提供了包含这些化合物或药物可接受的盐的药物组合物，以及使用这些化合物、药物可接受的盐和药物组合物治疗各种疾病，包括疼痛的方法。
• [EN] HERBICIDAL PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSÉS HERBICIDES DE PYRIMIDINE
  申请人：BASF SE

  公开号：WO2018019552A1

  公开（公告）日：2018-02-01

  The present invention relates to the pyrimidine compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of pyrimidine compounds of formula (I) as herbicide, compositions comprising them and their use as herbicides, i.e. for controlling harmful plants, and also a method for controlling unwanted vegetation which comprises allowing a herbicidal effective amount of at least one pyrimidine compounds of the formula (I) to act on plants, their seed and/or their habitat.

  本发明涉及式(I)的嘧啶化合物，或其在农业上可接受的盐或衍生物作为除草剂，其中变量根据描述定义，使用式(I)的嘧啶化合物作为除草剂，包含它们的组合物以及它们作为除草剂的用途，即用于控制有害植物，还涉及一种控制不受欢迎植被的方法，包括让式(I)的至少一种嘧啶化合物的除草有效量作用于植物、它们的种子和/或它们的栖息地。